Anixa Biosciences Inc (NASDAQ:ANIX – Get Free Report) CEO Amit Kumar purchased 3,000 shares of the company’s stock in a transaction that occurred on Friday, July 24th. The stock was acquired at an average cost of $3.73 per share, for a total transaction of $11,190.00. Following the transaction, the chief executive officer owned 643,812 shares in the company, valued at $2,401,418.76. This represents a 0.47% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Amit Kumar also recently made the following trade(s):
- On Monday, July 20th, Amit Kumar acquired 5,000 shares of Anixa Biosciences stock. The shares were bought at an average price of $3.46 per share, for a total transaction of $17,300.00.
- On Monday, July 27th, Amit Kumar purchased 3,188 shares of Anixa Biosciences stock. The shares were purchased at an average price of $3.37 per share, for a total transaction of $10,743.56.
- On Monday, July 27th, Amit Kumar purchased 5,000 shares of Anixa Biosciences stock. The shares were acquired at an average cost of $3.44 per share, with a total value of $17,200.00.
- On Friday, July 10th, Amit Kumar purchased 5,000 shares of Anixa Biosciences stock. The shares were bought at an average price of $3.04 per share, with a total value of $15,200.00.
- On Friday, June 12th, Amit Kumar purchased 21,000 shares of Anixa Biosciences stock. The shares were bought at an average price of $2.50 per share, with a total value of $52,500.00.
Anixa Biosciences Trading Up 2.6%
Shares of ANIX stock traded up $0.09 on Tuesday, hitting $3.55. 172,348 shares of the stock were exchanged, compared to its average volume of 178,140. The firm’s 50 day moving average is $2.91 and its two-hundred day moving average is $2.92. Anixa Biosciences Inc has a one year low of $2.32 and a one year high of $5.46. The firm has a market capitalization of $120.78 million, a PE ratio of -11.45 and a beta of 0.59.
Hedge Funds Weigh In On Anixa Biosciences
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. NewEdge Advisors LLC bought a new position in Anixa Biosciences in the 2nd quarter worth $33,000. Cetera Investment Advisers bought a new position in Anixa Biosciences in the fourth quarter worth about $35,000. Northwestern Mutual Wealth Management Co. lifted its holdings in Anixa Biosciences by 2,000.0% in the third quarter. Northwestern Mutual Wealth Management Co. now owns 10,500 shares of the company’s stock worth $35,000 after buying an additional 10,000 shares during the period. Benjamin Edwards Inc. bought a new stake in Anixa Biosciences during the 2nd quarter valued at approximately $37,000. Finally, Millennium Management LLC purchased a new position in shares of Anixa Biosciences during the 4th quarter worth approximately $38,000. Institutional investors own 29.13% of the company’s stock.
Analyst Upgrades and Downgrades
ANIX has been the topic of several research reports. Wall Street Zen upgraded shares of Anixa Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, June 20th. HC Wainwright reissued a “buy” rating on shares of Anixa Biosciences in a research note on Friday, June 12th. Weiss Ratings restated a “sell (e+)” rating on shares of Anixa Biosciences in a research report on Wednesday, June 17th. Citigroup reiterated a “buy” rating on shares of Anixa Biosciences in a report on Friday, June 12th. Finally, D. Boral Capital reiterated a “buy” rating and set a $10.00 price objective on shares of Anixa Biosciences in a research report on Tuesday, June 30th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $8.50.
Check Out Our Latest Stock Analysis on ANIX
Anixa Biosciences Company Profile
Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.
In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.
Featured Stories
- Five stocks we like better than Anixa Biosciences
- Western Digital’s Earnings Will Test Whether Its AI Rally Has More Room
- Is the Market Mispricing ServiceNow’s AI Future?
- Nano Nuclear’s Air Force Contract Puts Its Short-Squeeze Setup in Focus
- Amkor Sells Off After Earnings—Why Weak Guidance Isn’t the Real Story
Receive News & Ratings for Anixa Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anixa Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
